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Abstract 
Platelet-activating factor (PAF) is a phospholipid compound with major immunoregulatory activities. The present study shows that 
human bone marrow contains 576 + 39 pg PAF/ml (n = 35). Bone marrow-derived PAF exhibits the same biophysical and biological 
properties that synthetic PAF. PAF concentrations in bone marrow are correlated with the granulocyte (r = 0.4, P = 0.02) but not with 
the lymphocyte (r = 0.24, P = 0.17) and the monocyte (r = 0.12, P = 0.48) counts. In bone marrow PAF is inactivated by a plasma PAF 
acetylhydrolase activity (48.0 ___ 2.3 nmol/min per ml, n = 34). Experiments with [3H]PAF indicate that human bone marrow cells 
actively metabolize this potent molecule by the deacetylation-transacylation pathway. Results of this investigation i dicate the permanent 
presence of significant amounts of PAF in bone marrow suggesting its putative involvement in the processes of bone marrow cell 
proliferation and maturation. 
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1. Introduction 
Platelet-activating factor (PAF) is a phospholipidic 
compound which is produced and acts on a wide range of 
cells and organs [1-3]. PAF levels are regulated by the 
enzyme PAF acetylhydrolase which is present in plasma 
and tissues [4,5]. PAF exhibits potent immunoregulatory 
activities on blood cells suc]h as T and B lymphocytes, 
basophils, eosinophils, monocytes and neutrophils [6-11], 
and enhances the maturation and differentiation of ba- 
sophils and eosinophils from ]hematopoietic precursor cells 
from human umbilical cord blood [12,13]. PAF stimulates 
DNA synthesis in guinea pig: and rabbit bone marrow in 
vitro [14,15]. Recently we have reported the presence of 
PAF in femoral bone marrow of rats [16]. Taking all these 
results into account, we attempted to establish for the first 
time the presence of PAF and acetylhydrolase activity in 
normal human bone marrow, to correlate PAF amounts 
and acetylhydrolase activity with bone marrow cell counts, 
and to examine PAF uptake and metabolism by bone 
marrow cells. These data could be of importance for later 
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investigations of the putative role of PAF in the prolifera- 
tion and maturation processes of human bone marrow 
cells. 
2. Materials and methods 
2.1. Patients 
This study was performed according to the Helsinki 
recommendations. Sternum bone marrow samples were 
harvested from untreated patients referred for diagnosis. 
All samples used in this study exhibited a normal myelo- 
gram. One-ml bone marrow samples were collected on 
ethanol to assess PAF content. Aliquots of bone marrow 
samples were used to assess total cellular content using a 
hemocytometer. Aliquots of bone marrow samples were 
recovered on EDTA anticoagulated tubes (Vacutainer sys- 
tem, Becton Dickinson, Meylan, France) and centrifuged 
(400 X g, 10 min). Plasma samples were collected and 
stored at -80°C  until assay of the PAF acetylhydrolase 
activity. In separate xperiments, 1-ml bone marrow sam- 
ples were recovered on EDTA and centrifuged (400 × g, 
10 min, 4°C). Plasma and cell-associated PAF were sepa- 
rately assessed. 
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As controls, 1-ml blood samples from healthy volun- 
teers were recovered on ethanol to assess blood PAF 
levels. 
2.2. Processing of samples for PAF determinations 
plasma (nmol/min/ml) as means of duplicate determina- 
tions. The variation between duplicates was less than 5%. 
2.6. [3H]PAF uptake and metabolism by human bone 
marrow cells 
Samples were immediately mixed with four volumes of 
ethanol (80% final). Lipids were ethanol-extracted during 
10 h [17]. Samples were centrifuged (3000 X g, 15 min). 
Supernatants were dried and recovered with 200 /zl of 
chloroform/methanol (1:1, v/v). Phospholipids were puri- 
fied on thin-layer chromatography (TLC) plates (Silica gel 
60 (20 X 20 cm, 0.5 mm), Merck). The plates were devel- 
oped in the mixture of chloroform/methanol/water 
(70:35:5, v/v)  [18]. [3H] PAF was used as marker. Areas 
of samples on TLC plates with RF values corresponding to 
the PAF standard were extracted, suspended in 60% 
ethanol, and assayed for PAF activity. 
2.3. PAF assay 
PAF activity was measured by platelet aggregation 
using a Labintec aggregometer [16,19]. Aspirin-treated 
washed rabbit platelets were stirred in 300 /zl Tyrode 
buffer containing 0.25% gelatin, 1 mM creatine phosphate, 
and 10 U/ml creatine phosphokinase (pH 7.4). Aggregat- 
ing activity of the samples were measured using a calibra- 
tion curve obtained with 2.5 to 20 pg of synthetic PAF 
(Novabiochem, Switzerland). 
2.4. PAF characterization 
The lipidic compound extracted from bone marrow was 
further characterized on the basis of the following criteria: 
(1) study of the aggregating activity in the presence of 0.1 
mM CV 3988 (Takeda Chemical, Osaka, Japan) a specific 
PAF receptor antagonist [20]; (2) the same after incubation 
of the samples with phospholipase A2 from hog pancreas 
and lipase A1 from R. arrhizus [21]; and (3) retention time 
during TLC [18]. 
2.5. PAF acetylhydrolase assay 
PAF acetylhydrolase activity was assessed according to 
the method of Miwa et al. with minor modifications [22]. 
Briefly, 10 5 dpm of 1-O-alkyl-2-[3H]acetyl - 
glycerophosphocholine ([3H]acetyl-PAF; 10 Ci/mmol; 
NEN), 0.1 mM PAF, Hepes buffer (pH 7.8) in a final 
volume of 450/xl, and 50/xl diluted plasma (1:50 dilution 
in Hepes buffer) were incubated for 10 min at 37°C. The 
reaction was stopped with 100 /zl bovine serum albumin 
(10%) and 400/zl trichloracetic acid (20%). Samples were 
centrifuged (1500 x g, 15 min) and supernatants were 
counted in a liquid scintillation counter. Results were 
expressed as nanomoles PAF degraded per min per ml of 
Human mononuclear bone marrow cells obtained from 
heparinized samples and isolated on Ficoll (280 X g; 20 
min) were washed with Hanks' balanced salts solution 
(HBSS) and resuspended in RPMI 1640 without serum 
(Gibco, France). Cells (5 • 10  6 cells/tube) were incubated 
at 37°C in a volume of 0.5 ml for various periods of time 
in the presence of [3H]alkyl-PAF (Amersham, France) 
(final concentration 0.05 nmol/tube; 0.5 /zCi) complexed 
to human serum albumin (final concentration 2 mg/ml). 
Experiments were performed in quadriplicate. One set of 
duplicates was used to quantify uptake and the other to 
quantify metabolism. 
To assess PAF metabolism incubations were terminated 
by the addition of methanol/chloroform (2:1, v/v)  to the 
reaction mixture, and the lipids were extracted by the 
method of Bligh and Dyer [23]. In these experiments he 
labeled products recovered include both those in the 
medium and those associated with the cells. Recovery of 
added radioactivity after lipid extraction was 85%. The 
labeled compounds derived from [3H]alkyl-PAF were sep- 
arated using TLC plates (Silica Gel 60 (20 X 20 cm, 0.25 
mm), Merck, France) developed in chloroform/ 
methanol/acetic a id/water (50:25:8:4, v/v)  [24]. Each 
lane was divided in areas of 0.5 cm length which were 
scraped into vials and radioactivity was measured on a 
Packard liquid scintillation counter. Unlabeled PAF (1-O- 
alkyl-2-acetyl-glycerophosphocholine), lyso PAF (1-O-al- 
kyl-2-1yso-glycerophosphocholine), phosphatidylcholine 
(1-O-alkyl-2-acyl-glycerophosphocholine) and neutral lipid 
(1-O-alkyl-2-acetyl-glycerol) were used as standards and 
were visualized with iodine vapour. 
2.7. Statistical analysis 
Results are reported as mean + S.E. or as individual 
data. Correlations between PAF level, acetylhydrolase ac- 
tivity and cell counts were calculated by linear regression 
analysis. 
3. Results 
We first investigated the presence of PAF in human 
sternum bone marrow samples. As shown in Fig. 1, lipids 
extracted from all bone marrow specimens exhibit a PAF- 
like activity with a mean level of 576_ 39 pg PAF/ml 
(n = 35). Bone marrow PAF amounts are significantly 
elevated (P= 0.0001, Mann-Whitney U test) as com- 
pared to blood PAF amounts in healthy controls (374 + 22 
pg PAF/ml, n = 24). The plasma- and cell-associated 
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F ig .  1. PAF  in  human bone  marrow.  Resu l t s  are  expressed  in p icograms 
PAF  per  ml  o f  bone  marrow ( ind iv idua l  data) .  
PAF have been investigated. Results show that 58.8 + 1.6% 
(n = 10) of the PAF in human bone marrow is cell-associ- 
ated. The PAF-like material recovered from bone marrow 
samples has biological and physicochemical characteristics 
identical to those of authentic PAF: (1) it induces the 
aggregation of washed rabbit platelets that are refractory to 
arachidonic acid and ADP-mediated pathways (Fig. 2); (2) 
The platelet aggregating activity is totally inhibited by the 
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F ig .  3. PAF  acety lhydro lase  ac t iv i ty  in  p lasma o f  human bone  marrow.  
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( ind iv idua l  data) .  
PAF antagonist CV 3988 (Fig. 2); The aggregating activity 
is sensitive to phospholipase A 2 but not to lipase A1 (data 
not shown); (3) The PAF-like material exhibits on TLC a 
retention time similar to that of synthetic PAF (data not 
shown). These results indicate that the material recovered 
from human bone marrow samples is PAF. 
In order to investigate the putative cellular origin of the 
bone marrow-derived PAF, correlations were performed 
between bone marrow PAF contents and the counts of 
erythroblasts, granulocytes, monocytes and lymphocytes. 
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Fig. 4. Distribution of label in products after incubation of [3H]alkyl-PAF 
with human bone marrow cells for 60 min at 37°C. PAF, 1-O-alkyl-2- 
acetyl-glycerophosphocholine; Lyso PAF, 1-O-alkyl-2-1yso- 
glycerophosphocholine; PC, 1-O-alkyl-2-acyl-glycerophosphocholine; 
NL, neutral lipid. One representative tracing of five independent experi- 
ments is shown. 
5, 10, 20 and 60 min of incubation bone marrow cells 
incorporate 51, 62, 70 and 76% of the initially added 
radioactivity (n = 3). A representative TLC profile of la- 
beled metabolites of PAF is reported in Fig. 4. When 
[3H]PAF is incubated with bone marrow cells for 1 h the 
label migrates with PAF and phosphatidylcholine (i. . with 
a long chain acyl group at the sn-2 position of the glycerol 
backbone). The distribution of label as a function of time 
is reported in Fig. 5. At each time point, less than 6% of 
the radioactivity migrates with lyso PAF or neutral ipids. 
The time-dependent decrease of [3H]PAF is paralleled 
with the time-dependent increase of [3H]phosphatidyl- 
choline. Incubations of [3H]PAF for 3 h in the absence of 
bone marrow cells result in no appreciable catabolism 
(data not shown). 
4. Discussion 
Significant correlations were found between PAF amounts 
and granulocyte counts (r  = 0.4, P = 0.02) but not with 
erythroblast (r = 0.14, P = 0.4), lymphocyte (r  = 0.24, 
P = 0.17) and monocyte (r = 0.12, P --- 0.48) counts. 
We also investigated the presence of a PAF acetylhy- 
drolase activity in human bone marrow plasma samples. 
As shown in Fig. 3, a PAF acetylhydrolase activity is 
detected in all bone marrow plasmas at the mean levels of 
48.0 ___ 2.3 nmol PAF /min /ml  (n = 34). No correlation is 
documented between PAF levels and acetylhydrolase ac- 
tivity (r  = 0.09, P = 0.58). No correlation is documented 
between PAF acetylhydrolase activity and the various cell 
counts (data not shown). 
In the next set of experiments bone marrow mononu- 
clear cells were incubated with labeled PAF for 5 min to 3 
h after which uptake and metabolism were assessed. After 
100- 
80 
- 60- 
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~ 2o 
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min  
Fig. 5. Time-course of the conversion of 1-O-[3H]alkyl-2-acetyl-glycero - 
phosphocholine ( ©) to 1 -O-[ 3 H]alkyl-2-acyl-glycerophosphocholine (O), 
1-O-[3H]alkyl-2-1yso-glycerophosphocholine ( • ), and [3 H]-neutral lipids 
(O) in human bone marrow cells. Results are expressed as the percentage 
of total radioactivity recovered following incubation of bone marrow cells 
with [3H]PAF using the conditions described in Section 2. The values are 
the mean of five independent experiments. 
The present work reports the presence of PAF and PAF 
acetylhydrolase activity in human bone marrow and the 
catabolism of PAF by human bone marrow cells. The 
platelet aggregation method is a sensitive assay that can be 
used to detect picogram quantities of PAF in biological 
samples [25]. Lipid extraction and TLC purification before 
assay ensure the accuracy of the results [26]. Furthermore, 
we use several experimental biological and physico- 
chemical criterias to demonstrate hat the PAF-like mate- 
rial recovered from human bone marrow was PAF. 
In this study PAF was detected in all human bone 
marrow samples tested with a mean level of 576 _ 39 pg 
PAF per ml, i.e., significantly elevated as compared to 
blood PAF levels (374_ 22 pg per ml). At this time we 
cannot firmly exclude that circulating blood PAF does not 
account for a small part of the PAF found in human bone 
marrow. The PAF acetylhydrolase activity in bone marrow 
plasma (48.0 + 2.3 nmol PAF/min per ml, n = 34) is 
rather similar to the one previously reported in human 
plasma [27-29]. 
The cellular origin of the bone marrow-derived PAF 
remains an open question. While PAF amounts are not 
correlated with lymphocyte, monocyte and erythroblast 
counts, a significant relation is documented between PAF 
levels and granulocyte counts. Interestingly, granulocytes 
produce PAF after in vitro stimulation [17,30,31] while the 
release of PAF from normal human lymphocytes i unsuc- 
cessful [17]. At this time the production of PAF by ery- 
throblasts i  not documented. After in vitro stimulation of 
blood cells most of the newly synthesized PAF remains 
cell-associated [30-33]. We find that only 60% of the PAF 
in human bone marrow is cell-associated. Unusually among 
human blood cell types, monocytes are reported to release 
significant amounts of their newly synthesized PAF [34]. 
However, there is no relation between PAF amounts and 
monocyte counts. We may thus suggest hat a part of the 
PAF found in bone marrow may originate from another 
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population such as epithelial and dendritic cells and/or 
fibroblasts. Of interest, human skin fibroblasts produce 
PAF in vitro and release halt' of their newly synthesized 
PAF [35]. This hypothesis also suggested to account for 
the high amounts of PAF present in human thymus [36]. 
Clearly the capacity of human bone marrow cells to pro- 
duce PAF deserves to be investigated. 
The catabolism of PAF is an effective mean by which 
cells can regulate its level. PAF is metabolized by numer- 
ous cells using the deacetylation-transacylation pathway. 
Accumulation of the deacetylated compound lyso PAF is 
found in human endothelial cells [37] and rat alveolar 
macrophages [38]. By contrast, in human monocytes [39], 
neutrophils [24] and lymphocytes [40] the major PAF 
metabolite is 1-O-alkyl-2-acyl-glycerophosphocholine. Re- 
sults of the present study indicate that human bone marrow 
cells metabolize PAF using the deacetylation-transacyla- 
tion pathway. Similarly to that found for human neu- 
trophils [24] and lymphocytes [40], the metabolite lyso 
PAF, which appears briefly in the system, is quikly reacy- 
lated with a fatty acid at the 2 position of the PAF glycerol 
backbone. The temporal relationships between the deacety- 
lation and reacylation of PAF found in human bone mar- 
row cells is in agreement with those found in human 
neutrophils and lymphocytes [24,40]. Thus, PAF is simi- 
larly metabolized in bone marrow and in peripheral blood. 
Is the 500 pg of PAF detected per ml of human bone 
marrow physiologicaly significant? High amounts of PAF 
are usually added to cell cultures because PAF is rapidly 
catabolized in the culture medium by serum or cellular 
PAF acetylhydrolase. Kato et al. report hat 55 /xg of PAF 
and 55 ng of a non-metabolizable PAF agonist enhance 
[3H]thymidine incorporation i freshly isolated guinea pig 
bone marrow cells [14]. Saito et al. report that 550 pg of 
PAF enhance both eosinophilic and basophilic differentia- 
tion in human hematopoietic precursor cells [12]. Finally, 
pM amounts of PAF induce interleukin-1 and tumor necro- 
sis factor production from human blood monocytes [41,42]. 
With respect o the plasma acetylhydrolase activity de- 
tected in human bone marrow and the capacity of bone 
marrow cells to metabolize PAF, we suggest a continuous 
local PAF synthesis in the bone marrow. The permanent 
presence of PAF in bone marrow may be compared to a 
continuous stimulation with low doses of PAF. The capac- 
ity of PAF to modulate the processes of human bone 
marrow cell proliferation and maturation is presently under 
investigation. 
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